Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 16 and 75 years old
- You have been diagnosed with a condition involving inflammation or damage to the protective coating of nerves in the brain or spinal cord (such as MS or a related condition)
- Information about your health and symptoms from when your condition first started is available
- You (and/or your parent or legal guardian, if applicable) are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You are unable to have an MRI scan for medical reasons (confirm with trial site)
- You are currently taking part in another clinical trial where you do not know whether you are receiving the actual treatment or a dummy treatment (a "blinded" trial)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yaou Liu, PhD, Beijing Tiantan Hospital
Phone: +86 1059975396
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The brain structural change over time between the baseline MRI and the follow-up MRIs; The spinal cord change over time between the baseline MRI and the follow-up MRIs.; The functional change over time between the baseline MRI and the follow-up MRIs.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.